Targeting the A3adenosine receptor for glaucoma treatment (Review)

Molecular Medicine Reports

Volumn 7, Issue 6, 2013, Pages 1723-1725

  Pnina, Fishman ^a   Shira, Cohen ^a   Bar Yehuda, Sara ^a  

^a Can Fite BioPharma   (Israel)

Author keywords

A3adenosine receptor; CF101; Glaucoma; Intraocular pressure

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; APOPTOSIS INDUCING FACTOR; CASPASE 3; CASPASE 9; CYTOCHROME C; NITRIC OXIDE; TIMOLOL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ADENOSINE; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AQUEOUS HUMOR FLOW; ARTICLE; AUTOIMMUNE UVEITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; GLAUCOMA; HUMAN; IN VITRO STUDY; INTRAOCULAR PRESSURE; MEMBRANE PERMEABILITY; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PSEUDOEXFOLIATION; RETINA GANGLION CELL; VISUAL IMPAIRMENT; WNT SIGNALING PATHWAY; CHEMISTRY; CYTOLOGY; DRUG EFFECT; METABOLISM; PATHOLOGY; REVIEW;

ADENOSINE; ADENOSINE A3 RECEPTOR AGONISTS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; DRY EYE SYNDROMES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; RECEPTOR, ADENOSINE A3; RETINAL GANGLION CELLS;

EID: 84877272473     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1413     Document Type: Article

References (34)

1. Varma R, Lee PP, Goldberg I and Kotak S: An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol 152: 515-522, 2011.
2. Fishman P, Bar-Yehuda S and Madi L: Adenosine, tumors and immunity. In: Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. Hasko G, Cronstein BN and Szabo C (eds). Taylor and Francis, London, pp299-312, 2007.
3. 3receptors reduces ischemic brain injury in rodents. J Neurosci Res 84: 1848-1855, 2006.
4. David M, Akerman L, Ziv M, et al: Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 26: 361-367, 2012.
5. Avni I, Garzozi HJ, Barequet IS, et al: Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology 117: 1287-1293, 2010.
6. 3adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol 35: 41-48, 2008.
7. Bagnis A, Papadia M, Scotto R and Traverso CE: Current and emerging medical therapies in the treatment of glaucoma. Expert Opin Emerg Drugs 16: 293-307, 2011.
8. Qu J, Wang D and Grosskreutz CL: Mechanisms of retinal ganglion cell injury and defense in glaucoma. Exp Eye Res 91: 48-53, 2010.
9. Nakazawa T, Nakazawa C, Matsubara A, et al: Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 26: 12633-12641, 2006.
10. Sivakumar V, Foulds WS, Luu CD, et al: Retinal ganglion cell death is induced by microglia derived pro-inflammatory cytokines in the hypoxic neonatal retina. J Pathol 224: 245-260, 2011.
11. Baudouin C, Liang H, Hamard P, et al: The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 115: 109-115, 2008.
12. Leske MC, Wu SY, Hennis A, et al; BESs Study Group: Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology 115: 85-93, 2008.
13. The European Glaucoma Society: Treatment principles and options. In: Terminology and Guidelines for Glaucoma. Heijl A and Traverso CE (eds). 3rd edition. Dogma SRL, Savona, pp117-131, 2008.
14. Reardon G, Kotak S and Schwartz GF: Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence 5: 441-463, 2011.
15. Strahlman E, Tipping R and Vogel R: A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 113: 1009-1016, 1995.
16. Baudouin C, Hamard P, Liang H, et al: Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 111: 2186-2192, 2004.
17. Pisella PJ, Debbasch C, Hamard P, et al: Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 45: 1360-1368, 2004.
18. Rusk C, Sharpe E, Laurence J, et al: Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group. Clin Ther 20: 454-466, 1998.
19. Katz LJ: Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 11: 119-126, 2002.
20. Feldman RM: Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 19: 23-35, 2003.
21. 3adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 226: 2438-2447, 2011.
22. 3adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269: 230-236, 2001.
23. 3adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care 10: R65, 2006.
24. Xu Z, Jang Y, Mueller RA and Norfleet EA: IB-MECA and cardioprotection. Cardiovasc Drug Rev 24: 227-238, 2006.
25. 3adenosine receptor. J Pharmacol Exp Ther 319: 1200-1210, 2006.
26. 2801, 2005.
27. 3adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells. Neurochem Int 56: 35-41, 2010.
28. 3adenosine receptors prevent loss following P2X7 receptor stimulation. J Neurochem 98: 566-575, 2006.
29. 3adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci 46: 2023-2034, 2005.
30. 3adenosine receptor in rat retinal ganglion cells. Mol Vis 12: 937-948, 2006.
31. Hu H, Lu W, Zhang M, et al: Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res 91: 425-432, 2010.
32. 3adenosine receptor agonist CF101. Int J Mol Med 28: 727-731, 2011.
33. 3adenosine receptors reduces mouse intraocular pressure. Invest Ophthalmol Vis Sci 43: 3021-3026, 2002.
34. Jacobson KA, von Lubitz DK, Daly JW and Fredholm BB: Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 17: 108-113, 1996.